Fulgent Genetics (FLGT) Liabilities and Shareholders Equity (2016 - 2026)
Fulgent Genetics' Liabilities and Shareholders Equity history spans 12 years, with the latest figure at $1.2 billion for Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity fell 4.09% to $1.2 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $4.8 billion, a 2.2% decrease, with the full-year FY2025 number at $1.2 billion, down 0.53% from a year prior.
- Liabilities and Shareholders Equity hit $1.2 billion in Q1 2026 for Fulgent Genetics, down from $1.2 billion in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for FLGT hit a ceiling of $1.5 billion in Q1 2022 and a floor of $93.2 million in Q4 2022.
- Historically, Liabilities and Shareholders Equity has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2024.
- Biggest five-year swings in Liabilities and Shareholders Equity: tumbled 92.71% in 2022 and later soared 1225.0% in 2023.
- Tracing FLGT's Liabilities and Shareholders Equity over 5 years: stood at $93.2 million in 2022, then soared by 1225.0% to $1.2 billion in 2023, then dropped by 1.24% to $1.2 billion in 2024, then decreased by 0.53% to $1.2 billion in 2025, then fell by 4.71% to $1.2 billion in 2026.
- Business Quant data shows Liabilities and Shareholders Equity for FLGT at $1.2 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.2 billion in Q3 2025.